{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-039225","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.152967+00:00","generated_at":"2026-05-26T02:27:45.772946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M","bullets":["Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).","Net loss improved to $6.0M from $12.1M in 2023; adjusted EBITDA $22.4M (+77% YoY).","Installed base reached 3,034 instruments; 667 placed in 2024.","Board authorized new $50M stock repurchase program for 2025; $21.6M repurchased in 2024.","2025 revenue guidance $204-212M (2-6% growth); opened Singapore manufacturing facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-039225","json":"https://secwatch.observer/filing/0001193125-25-039225.json","markdown":"https://secwatch.observer/filing/0001193125-25-039225.md","text":"https://secwatch.observer/filing/0001193125-25-039225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312525039225/0001193125-25-039225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312525039225/d829130d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:27:45.772946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}